The third annual report also shows that PledgeLA venture capital firms who are committed to making investments on companies led by traditionally underrepresented founders were 1.75 times more likely to fund women and 10 times more likely to fund Black founders.
#Kite pharma free
All of the data will remain open-source and free to the public. Which means report cards could soon be coming to the East Coast as well-a massive boon for the highly endangered North Atlantic right whale population.
#Kite pharma software
The team is also looking for a way to expand its vessel analytics software to the rest of North America. Today, Steffen says 62% of ships follow the technologies recommendations.īuoyed by the success, Whale Safe has recently set up a second operation off the coast of San Francisco. When Whale Safe first began in 2019, only 47% of ships heeded the recommendation, but in 2020 that number jumped to 54%. So far, the project appears to be working. Retailers and consumers now have a way to prove their goods are being moved in a whale-safe way, and shipping companies like it because it lets them check up on their colleagues and competition. The AIS data is obtained through Global Fishing Watch, but WhaleSafe processes the data to pull out the bits relevant to the whale zones they’re studying.Īt first glance, it might seem like industry would hate this kind of oversight, but Steffen says there’s a lot of demand for these data from various stakeholders. The analytics are captured from each ship’s automatic identification system (AIS), which is essentially a GPS unit that large ships use to navigate and avoid collisions, says Steffen. “It's just a really easily digestible way to understand how much whale activity is happening in the Santa Barbara Channel on any given day.”įor now, the slowdowns are voluntary, but the second part of Whale Safe’s model is that it also collects data about which ships adhere to the warnings and issues public report cards for each company and the individual ships in their fleet. “The best way I can describe the whale presence rating is it's almost like a Smokey the Bear fire warning, but for whales,” says Callie Steffen, the lead scientist at Whale Safe. The FDA approved one of the pharma company's CAR-T treatments for a type of lymphoma cancer in 2017, and another was approved for what's known as mantle cell lymphoma cancer last year. This isn't Kite Pharma's first foray into CAR-T cell therapies.
Kang said they partnered with Kite because it already had manufacturing facilities as well as an infrastructure for development and research. "We hope to provide allogeneic cell therapy as a broadly accessible next-generation therapeutic option for oncologists and their patients," said Appia Bio CEO JJ Kang in an email.Īppia Bio hopes this will create safe therapies at scale, allowing doctors to start treatment almost immediately instead of making late-stage cancer patients wait long time periods as their cells are engineered. The company's patented technology, ACUA, uses allogeneic cells to generate iNKT cells, which may be less likely to be rejected by the patient's immune system. Unlike most cell therapies that come from cells of the patient, known as autologous cell therapy, Appia Bio will use the cells of other people, known as allogeneic cell therapy. Pharma giant Gilead Sciences announced in 2017 it would acquire Kite Pharma in a nearly $12 billion deal, pointing to a growing interest in Los Angeles' bioscience community made up of university-to-startup pipelines like Appia, which has founders from UCLA, USC and CalTech.Īppia Bio will be responsible for doing preclinical and early clinical research of engineered cells provided by Kite, and Kite Pharma will be responsible for developing, manufacturing and commercializing the therapies.
The deal highlights a growing, collaborative ecosystem in Los Angeles reminiscent of the biotech community in San Diego. The deal could be worth up to $875 million for Appia Bio, according to the two companies. Under the agreement, Westwood-based Appia Bio ( which came out of stealth in May) and Kite Pharma will develop CAR-T cell therapies, a promising new treatment that aims to eliminate cancer cells and strengthen the immune system's response to flag and fight these cells in the future. Last week, one of the biggest players in cell therapy, Kite Pharma, announced it will work with the cancer startup Appia Bio to create breakthrough drugs.
Treatments are being developed by two Southern California pharma companies. The next wave of cancer treatments uses the body's own immune system rather than chemotherapy or radiation to kill cancer cells.
0 kommentar(er)
